PAUL JAY MARKOVITZ, M.D., PH.D.
-Curriculum Vitae-
: 2101 Richmond RoadOFFICE ADDRESS
La Place Suite 1030
Beachwood, Ohio 44122-1390
Telephone: (216) 591-0006
Fax: (216) 591-0104
EDUCATION:
8/82 - 5/85 M.D.
5/77 - 6/78 Case Western Reserve University
Cleveland, Ohio 44106
7/78 - 6/82 Ph.D. Biochemistry
Case Western Reserve University
Cleveland, Ohio 44106
8/73 - 5/77 B.A. Chemistry
Case Western Reserve University
Cleveland, Ohio 44106
PROFESSIONAL TRAINING:
7/87 - 6/89 Residency Program in Psychiatry
The Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, Ohio 44106
6/86 - 6/87 Postdoctoral Fellow in Neuropharmacology
MRC Department of Clinical Pharmacology
Oxford University
Radcliffe Infirmary
Oxford, U.K. OX2 6HE
7/85 - 6/86 Residency Program in Psychiatry
University Hospitals of Cleveland
2074 Abington Road
Cleveland, Ohio 44106
9/84 - 7/85 Postdoctoral Fellow in Human Genetics
Veterans' Administration and Dept. of Medicine
Case Western Reserve University
Cleveland, Ohio 44106
PROFESSIONAL APPOINTMENTS:
7/93 - present Assistant Clinical Professor of Psychiatry Case Western Reserve University School of Medicine
Cleveland, Ohio 44106
7/93 - present Director, Mood and Anxiety Research Center, Inc.
Director, Psychiatric Development Research, Inc.
2101 Richmond Road Suite 1030
Beachwood, Ohio 44122-1390
10/93 - 12/94 Medical Director, Progressive Clinical Services of Cleveland
90251 Rockside Road
Valley View, Ohio 44125
7/90 - 6/93 Assistant Professor of Psychiatry
Case Western Reserve University
School of Medicine
Director, Personality Disorders Program
University Hospitals of Cleveland
11400 Euclid Avenue Suite 200
Cleveland, Ohio 44106
10/89 - 6/90 Clinical Instructor
Department of Psychiatry
University Hospitals of Cleveland
2074 Abington Road
Cleveland, Ohio 44106
HONORS & AWARDS:
4/90 First Place - Ohio Psychiatric Association Award in
recognition of outstanding research during 1989
6/89 Richard M. Steinhilber Award in recognition of the pursuit of
knowledge and research excellence in the 1989 academic year
6/89 First Place Research Award in Basic Sciences at the Cleveland Clinic Foundation's Annual Psychiatry and Psychology Research Day
6/86 - 6/87 NATO Postdoctoral Fellowship in Science awarded through
the National Science Foundation for study abroad
8/77 - 5/85 Medical Scientist Training Program
Case Western Reserve University
5/77 Graduated cum laude
Case Western Reserve University
8/73 - 5/74 Presidential Scholarship
Case Western Reserve University
OHIO MEDICAL LICENSE: 35-05-4221
AFFILIATIONS: American Psychiatric Association
Ohio Psychiatric Association
Cleveland Psychiatric Association
Society of Biological Psychiatry
International Society for the Study of Personality
Society of Biological Psychiatry
REFEREE - JOURNALS: Journal of Clinical Psychopharmacology
Journal of Clinical Psychiatry
Neurology
Psychiatric Research Communications
American Psychiatric Association - ratings manual
COURSE WORK: Nonequilibrium Thermodynamics
Physical Biochemistry
Physical Chemistry
Pharmacokinetics
Protein Synthesis and Initiation
Lipid Metabolism and Membrane Biochemistry
Medical School curriculum of basic science and pathology
Medical School curriculum of clinical science
LABORATORY SKILLS: Column Chromatography
Isoelectric Focusing
HPLC
Carbon and Proton NMR
Centrifugation Techniques
Protein Purification
DNA, RNA, and Protein Electrophoresis
Organic Synthesis
Enzymatic Synthesis of Substrates
Antibody Production
Superfusion Techniques
Enzymatic Assays and Kinetics
BOARD CERTIFICATION: American Board of Psychiatry & Neurology
BIBLIOGRAPHY
ABSTRACTS:
1. Markovitz, PJ, Hanson, RW, Utter, MF: Induction of guinea pig cytosolic and mitochondrial phosphoenolpyruvate cCarboxykinase synthesis by cyclic-AMP, Federation Proceedings, February 1982.
2. Markovitz, PJ, Stagno, SJ, Calabrese, JR: Buspirone augmentation of fluoxetine in obsessive-compulsive disorder: An open add-on trial. Presented at Society of Biological Psychiatry Annual Meeting, May 1989.
3. Markovitz, PJ, Calabrese, JR, Schulz, SC: Fluoxetine in borderline personality disorder. Abstract presented at Society of Biological Psychiatry Annual Meeting, May 1990.
4. Markovitz, PJ, Calabrese, JR, Meltzer, HY, Schulz, SC: Fluoxetine in borderline personality disorder. Presented at National Clinical Drug Evaluation Unit Meetings (NCDEU), Key Biscayne, Florida, May 1990.
5. Calabrese JR, Delucchi, GA, Markovitz, PJ: Alternative agents in the treatment of manic depression: Focus on cycle frequency, duration, and amplitude. Abstract presented at Society of Biological Psychiatry Annual Meeting, May, 1990.
6. Markovitz, PJ, Calabrese JR, Schulz, SC, Trivedi C, Wagner S, Meltzer, HY: Comorbidity and treatment of borderline personality disorder. Abstract presented at International Convention on Treatment Refractory Depression, Amsterdam, Netherlands, June 25, 1992.
7. Markovitz, PJ, Comorbidity of migraines, PMS, IBS, fibromyalgia, neurodermatitis, and sleep apnea in borderline personality disorder: a possible serotonin link. Presented at the World Health Organization meeting on Personality Disorders, Cambridge, MA, September 1993.
8. Markovitz, PJ: Longitudinal efficacy of pharmacotherapy in borderline personality disorder: efficacy of sertraline and fluoxetine. Presented at the World Health Organization meeting on Personality Disorders, Cambridge, MA, September 1993.
9. Markovitz, PJ, Wagner, S: An open trial of venlafaxine in borderline personality disorder. Presented at National Clinical Drug Evaluation Unit Meetings (NCDEU), Orlando, Florida, May 1995.
10. Markovitz, PJ, Wagner, S, Stern HD: An open trial of venlafaxine in borderline personality disorder. Presented at the International Society for the Study of Personality Disorders, Dublin, Ireland, June, 1995.
11. Markovitz, PJ, Wagner, S, Stern HD: Selective serotonin reuptake inhibitors in borderline personality disorder: Correlation of Outcome with Sertraline, but not Fluoxetine or Paroxetine Serum Levels. . Presented at the International Society for the Study of Personality Disorders, Dublin, Ireland, June, 1995.
12. Markovitz, PJ, Wagner S: An open trial of venlafaxine in 68 patients with borderline personality disorder. Presented at the American Psychiatric Association Annual meeting. May, 1996.
13. Markovitz, PJ, Wagner S: An open trial of once versus twice daily nefazodone. Presented at American Psychiatric Association Annual Meeting, May 20, 1997. Abstract NR222.
14. Preskorn SH, Markovitz, PJ, Stahl SM, Ryan M, Borian FE, Hamid, S, Ieni JR, Jody DN: Once daily dosing of nefazodone for the treatment of depression in patients previously stabilized on
twice daily dosing. Presented at American Psychiatric Association Annual Meeting, May 20, 1997. Abstract NR224.
15. Markovitz PJ, Wagner SW. Venlafaxine in the treatment of somatic disorders in depressed and non-depressed patients. Presented at the American Psychiatric Association Annual Meeting, May 22, 1998.
ARTICLES:
1. Duffy, TH, Markovitz, PJ, Chuang, DT, Utter, MF, Nowak, T: Comparative Inhibition of Mitochondrial and Cytosolic Phosphoenolpyruvate Carboxykinase by Stereospecific Substrate Analogs. Proc. Natl. Acad. Sci., 78:11:6680-6683, 1981.
2. Shew, KF, Ho, HT, Nolan, LD, Markovitz, PJ, Richard, JP, Utter, MF, Frey, PA: Stereochemical Course of Thiophosphoryl Group Transfer Catalyzed by Mitochondrial Phosphoenolpyruvate Carboxykinase. Biochemistry, 23:8:1779-1783, 1984.
3. Markovitz, PJ, Chuang, DT, Cox, RP: A Multifunctional Peptide Catalyzing the First Two Steps of Lysine Degradation. Am. Jr. Human Genetics, September, 1984.
4. Markovitz, PJ, Chuang, DT, Cox, RP: Familial Hyperlysinemias: Purification and Characterization of the Bifunctional Aminoadipic Semialdehyde Synthase with Lysine- Ketoglutarate Reductase and Saccharopine Dehydrogenase Activities. Jr. Biol. Chem., 259:19:11643-11646, October 10, 1984.
5. Cox RP, Markovitz, PJ, Chuang, DT: Familial Hyperlysinemias - Multiple Enzyme Deficiencies Associated with the Bifunctional Aminoadipic Semialdehyde Synthase. Trans. Am. Clin. Climatol. Assoc., 97:69-81, 1985.
6. Chuang DT, Hu, CWC, Ku, LS, Markovitz, PJ, Cox, RP: Subunit Structure of Dihydro- lipoyl Transacylase Complex of Branched Chain Ketoacid Dehydrogenase Complex from Bovine Liver: Characterization of the Inner Transacylase Core. Jr. Biol. Chem., 260:25:13779-13786, November 5, 1985.
7. Markovitz, PJ, Cox, RP, Chuang, DT: Proteolytic Separation of Lysine-Ketoglutarate Reductase and Saccharopine Dehydrogenase from the Bifunctional Aminoadipic Semialdehyde Synthase. Jr. Biol. Chem., 262:19:9353-9358, July 5, 1987.
8. Markovitz, PJ, Stagno, SJ, Calabrese, JR: Buspirone Augmentation of Fluoxetine in Obsessive Compulsive Disorder. Am. J. Psychiatry, 147:5:798-800, 1990.
9. Calabrese, JR, Markovitz, PJ: Treatment of Depression: New Pharmacological Approaches. Primary Care, 18:2:421-434, 1991.
10. Markovitz, PJ, Calabrese, JR, Schulz, SC, Meltzer, HY: Fluoxetine in Borderline and Schizotypal Personality Disorder. Am. J. Psychiatry, 148:8:1064-1067, 1991.
11. Calabrese, JR, Markovitz, PJ, Kimmel, SE: Spectrum of Efficacy of Valproate in 78 Rapid - Cycling Manic Depressives. J. Clin. Psychopharmacology, 12:1:535-538, 1992.
12. Calabrese, JR, Meltzer, HY, Markovitz, PJ: Clozapine Prophylaxis in Rapid Cycling Bipolar Disorder. J. Clin. Psychopharmacology, 11:396-397, 1991.
13. Markovitz, PJ: Treatment of Anxiety in the Elderly. J. Clin. Psychiatry, 54 S:64-68, 1993.
14. Markovitz, PJ, Wagner, SC: Venlafaxine in the Treatment of Borderline Personality Disorder. Psychopharmacol Bull., 31:773-777, 1995.
LETTERS:
1. Markovitz, PJ, Calabrese, JR: Anticonvulsants in Manic Depression During Pregnancy. Psychosomatics, 31:118,1990.
2. Sunkhuredi, K, Markovitz, PJ: Trazodone Treatment of Trichotilomania. Am. J. Psychiatry,
150:523-524, 1990.
3. Schwartz, E, Markovitz, PJ: Fluoxetine Responsivity Mediated by Serum Levels, Not Dose. J. Clin.Psychopharmacology,13:363-364, 1993.
BOOK CHAPTERS:
1. Markovitz, PJ: Pharmacotherapy of Impulsivity, Aggression, and Related Disorders in Impulsivity and Aggression, eds. Hollander E and Stein D. John Wiley and Sons, pp 263-291, 1995.
IN PRESS/SUBMITTED:
1. Markovitz, PJ, Trivedi C, Wagner, SC, Schulz, SC, Meltzer, HY, Thompson, P: A Double-Blind, Placebo Controlled Trial of Fluoxetine in Borderline Personality Disorder. Submitted J. Clin. Psychiatry.
2. Markovitz, PJ, Wagner, SC: Serum Sertraline Levels Correlate with Positive Outcome in Borderline Personality Disorder. Submitted J Clin. Psychopharmacology.
3. Markovitz, PJ, Wagner, SC: Nefazodone in the Treatment of Borderline Personality Disorder. Submitted J. Personality Disorders.
4. Markovitz, PJ, Wagner, SC: Efficacy of Serotonergic Antidepressants in the Treatment of Somatic Disorders: Review of the Literature. Manuscript in preparation.